Company

Clinical Highlights

Breaking News

DAXXIFY™ (daxibotulinumtoxinA – Ianm) for injection 
is approved for the temporary treatment of moderate 
to severe frown lines (glabellar lines) in adults.

Read More
FILTER
American Society for Dermatologic Surgery
Fabi, Sabrina G. MD et al.

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

August 6, 2021
American Society for Dermatologic Surgery
Green, Jeremy B. MD et al.

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

August 6, 2021
American Society for Dermatologic Surgery
Faivre, Jimmy et al.

Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers

January 21, 2021
American Society for Dermatologic Surgery
Cohen, Joel L. et al.

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program

February 8, 2021
American Society for Dermatologic Surgery
Dermatologic Surgery – Glogau, Richard MD*; Kontis, Theda C. MD†

Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection

August 16, 2021
Gary Monheit, M.D.

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

March 24, 2021
Joseph Jankovic M.D. et al

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study

March 3, 2018
What is Cervical Dystonia?
Dr. Joseph Jankovic

Learn More About Cervical Dystonia with Dr. Joseph Jankovic

Revance Reports Positive Results from ASPEN Phase 3 Trial of DaxibotulinumtoxinA for Injection of Cervical Dystonia
Revance Therapeutics

Revance Announces Top-Line Results for ASPEN-1

Dermatologic Surgery – Hema Sundaram, MD, FAAD, Ava Shamban, et al.

Efficacy and Safety of a New Resilient Hyaluronic Acid Filler in the Correction of Moderate-to-Severe Dynamic Perioral Rhytides: A 52-Week Prospective, Multicenter, Controlled, Randomized, Evaluator-Blinded Study

December 17, 2021
Glogau, Richard MD*; Kontis, Theda C. MD†

Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection

August 16, 2021
Dermatologic Surgery – Cohen, Joel L. et al.

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program

February 8, 2021
Dermatologic Surgery – Faivre, Jimmy et al.

Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers

January 21, 2021
Revance

Learn More About Cervical Dystonia with Dr. Joseph Jankovic

Revance

Revance Announces Top-Line Results for ASPEN-1

Dermatologic Surgery – Green, Jeremy B. MD et al.

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

August 6, 2020
Dermatologic Surgery – Fabi, Sabrina G. MD et al.

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

August 6, 2020
Dermatologic Surgery – Gary Monheit, M.D.

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

March 24, 2020
Journal of the American Academy of Dermatology – Vince Bertucci, M.D.

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

December 2, 2019
Dermatologic Surgery – Berthold Rzany, M.D. et al

Efficacy and Safety of 3 New Resilient Hyaluronic Acid Fillers, Crosslinked With Decreased BDDE, for the Treatment of Dynamic Wrinkles

October 10, 2019
Plastic and Reconstructive Surgery – Jean Carruthers M.D. et al

DaxibotulinumtoxinA in the treatment of glabellar lines. Results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

October 10, 2019
Journal of Cosmetic Dermatology – Joely Kaufman-Janette MD et al.

Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate‐to‐severe nasolabial folds: A 64‐week, prospective, multicenter, controlled, randomized, double‐blind and within‐subject study

August 24, 2019
Movement Disorders – Joseph Jankovic M.D. et al

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study

March 3, 2018
Dermatologic Surgery – Vince Bertucci M.D. et al

Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines. Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines

December 1, 2017
Dermatologic Surgery – Jean Carruthers M.D. et al

Injectable DaxibotulinumtoxinA for the Treatment of Glabellar Lines. A Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Comparison With OnabotulinumtoxinA and Placebo

November 1, 2017
Dermatologic Surgery – Enrique Garcia-Murray M.D. et al

Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines

January 1, 2015

DISCLAIMER
DaxibotulinumtoxinA for Injection is an investigational agent that has not
been approved by the FDA and is currently under regulatory review.

* DaxibotulinumtoxinA for Injection was formerly known as RT002.

Read More

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY is not approved for the treatment of spasticity or any conditions other than glabellar lines.

IMPORTANT SAFETY INFORMATION  

Contraindications
DAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the  components in the formulation and infection at the injection site(s).  

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.  

The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.  

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).  

Drug Interactions
Co-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.  

Use in Specific Populations
DAXXIFY™ is not recommended for use in children or pregnant women.  

Please see DAXXIFYfull Prescribing Information, including Boxed Warning and Medication Guide.